Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan L Weiner

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Veterinary Ophthalmology|December 25, 2010
Advancements in ocular drug deliveryAlan L Weiner, Brian C Gilger
Pharmaceutical Development and Technology|April 2, 2008
Controlled flow-through dissolution methodology: a high-performance systemLarry E Stevens, Paul J Missel, Alan L Weiner
Ophthalmology|May 3, 2002
Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trialRonald L Fellman, E Kenneth Sullivan, Marla Ratliff, et al.
Advances in Therapy|September 6, 2003
Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertensionPeter A Netland, Stella M Robertson, E Kenneth Sullivan, et al.
The Ocular Surface|July 25, 2017
TFOS DEWS II iatrogenic reportJosé Alvaro P Gomes, Dimitri T Azar, Christophe Baudouin, et al.
Survey of Ophthalmology|September 3, 2002
Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonistMark R Hellberg, Marsha A McLaughlin, Naj A Sharif, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Veterinary Ophthalmology|December 25, 2010
Advancements in ocular drug deliveryAlan L Weiner, Brian C Gilger
Pharmaceutical Development and Technology|April 2, 2008
Controlled flow-through dissolution methodology: a high-performance systemLarry E Stevens, Paul J Missel, Alan L Weiner
Ophthalmology|May 3, 2002
Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trialRonald L Fellman, E Kenneth Sullivan, Marla Ratliff, et al.
Advances in Therapy|September 6, 2003
Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertensionPeter A Netland, Stella M Robertson, E Kenneth Sullivan, et al.
The Ocular Surface|July 25, 2017
TFOS DEWS II iatrogenic reportJosé Alvaro P Gomes, Dimitri T Azar, Christophe Baudouin, et al.
Survey of Ophthalmology|September 3, 2002
Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonistMark R Hellberg, Marsha A McLaughlin, Naj A Sharif, et al.
Pageof 1